Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn's diseaseShow others and affiliations
2012 (English)In: Alimentary Pharmacology and Therapeutics, ISSN 0269-2813, E-ISSN 1365-2036, Vol. 36, no 2, p. 151-158Article in journal (Refereed) Published
Abstract [en]
Background: Bowel strictures are a major cause of morbidity, hospitalisation and surgery in Crohn's disease.
Aim: We report short- and long-term efficacy and safety of endoscopic balloon dilation of strictures due to Crohn's disease.
Methods: Retrospective study of patients who underwent endoscopic balloon dilation between 1987 and 2009.
Results: We performed 776 dilations, of which 621 (80%) were on anastomotic strictures, in 178 patients (94 women) with Crohn's disease. At first dilation, median (IQR) age of patients was 45 (37-56) years and disease duration 16 (8-22) years. Technical success rate was 689/776 (89%). A subset of 75 patients from the primary catchment area, with >5-year follow-up, underwent a total of 246 dilations. At 1-year follow-up, 60/75 (80%) patients had undergone no further intervention or one additional dilation only. At 3 and 5 years, corresponding figures were 43/75 (57%) and 39/75 (52%). Cumulative proportions of patients undergoing surgery at 1, 3 and 5 years were 13%, 28% and 36%. Complication rate per procedure for all 178 patients was 41/776 (5.3%), bowel perforation (n = 11, 1.4%), major bleeding requiring blood transfusion (n = 8, 1.0%), minor bleeding (n = 10, 1.3%) and abdominal pain or fever (n = 12, 1.5%). Ten patients underwent surgery due to complications (perforation n = 8, bleeding n = 2). There was no procedure-related mortality.
Conclusion: Endoscopic balloon dilation is an efficacious and safe alternative to surgical resection of intestinal strictures in Crohn's disease. At 5-year follow-up, 52% of patients required no further or one additional dilation only, whereas 36% had undergone surgical resection. Complication frequency was low.
Place, publisher, year, edition, pages
Hoboken, USA: Wiley-Blackwell, 2012. Vol. 36, no 2, p. 151-158
National Category
Gastroenterology and Hepatology
Research subject
Medicine
Identifiers
URN: urn:nbn:se:oru:diva-24220DOI: 10.1111/j.1365-2036.2012.05146.xISI: 000305329000008PubMedID: 22612326Scopus ID: 2-s2.0-84862508948OAI: oai:DiVA.org:oru-24220DiVA, id: diva2:542829
Note
Funding Agencies:
Foundation for Clinical Research in Inflammatory Bowel Disease, United States
Uppsala-Örebro Regional Research Council, Sweden
2012-08-032012-08-032025-02-11Bibliographically approved
In thesis